- Home
- KIDS vs CGEM Comparison
KIDS vs CGEM Comparison
Compare KIDS & CGEM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- KIDS
- CGEM
- Stock Information
- Founded
- KIDS 2007
- CGEM 2016
- Country
- KIDS United States
- CGEM United States
- Employees
- KIDS N/A
- CGEM N/A
- Industry
- KIDS Medical/Dental Instruments
- CGEM Biotechnology: Pharmaceutical Preparations
- Sector
- KIDS Health Care
- CGEM Health Care
- Exchange
- KIDS Nasdaq
- CGEM Nasdaq
- Market Cap
- KIDS 524.3M
- CGEM 482.7M
- IPO Year
- KIDS 2017
- CGEM 2021
- Fundamental
- Price
- KIDS $20.91
- CGEM $6.84
- Analyst Decision
- KIDS Strong Buy
- CGEM Strong Buy
- Analyst Count
- KIDS 7
- CGEM 7
- Target Price
- KIDS $34.14
- CGEM $26.57
- AVG Volume (30 Days)
- KIDS 134.8K
- CGEM 445.0K
- Earning Date
- KIDS 11-05-2025
- CGEM 11-06-2025
- Dividend Yield
- KIDS N/A
- CGEM N/A
- EPS Growth
- KIDS N/A
- CGEM N/A
- EPS
- KIDS N/A
- CGEM N/A
- Revenue
- KIDS $220,733,000.00
- CGEM N/A
- Revenue This Year
- KIDS $19.26
- CGEM N/A
- Revenue Next Year
- KIDS $17.15
- CGEM N/A
- P/E Ratio
- KIDS N/A
- CGEM N/A
- Revenue Growth
- KIDS 26.08
- CGEM N/A
- 52 Week Low
- KIDS $16.59
- CGEM $6.61
- 52 Week High
- KIDS $33.14
- CGEM $18.62
- Technical
- Relative Strength Index (RSI)
- KIDS 52.31
- CGEM 39.08
- Support Level
- KIDS $20.29
- CGEM $6.61
- Resistance Level
- KIDS $21.35
- CGEM $7.82
- Average True Range (ATR)
- KIDS 0.88
- CGEM 0.45
- MACD
- KIDS 0.13
- CGEM -0.08
- Stochastic Oscillator
- KIDS 50.85
- CGEM 13.45
About KIDS OrthoPediatrics Corp.
OrthoPediatrics Corp is a medical device company. The company is engaged in providing products to the pediatric orthopedic market. The firm designs develop and commercialize implants and instruments to meet the needs of surgeons and patients. Its products, include PediLoc, PediPlates, Cannulated Screws, PediFlexTM nail, PediNailTM, PediLoc Tibia and ACL Reconstruction System among others.
About CGEM Cullinan Oncology Inc.
Cullinan Therapeutics Inc is a biopharmaceutical company. It has a diversified portfolio of clinical-stage assets that inhibit key drivers of disease or harness the immune system to eliminate diseased cells in both oncology and autoimmune diseases. Its understanding of oncology, immunology, and translational medicine, creates differentiated ideas, identifies the appropriate targets, and selects the optimal modality to develop transformative therapeutics across a variety of cancer and autoimmune indications. It has one reporting and one operating segment, which is the business of developing immunology and oncology therapies.